Even in Denmark — Novo Nordisk's house marketplace — an software for Wegovy to receive general public health and fitness insurance coverage coverage was rejected over the grounds that its cost was incommensurate with its therapeutic benefit.If the drug is found to own wider-reaching programs, which includes cardiovascular Added benefits, it is